Fig. 2

Establishing an emRNA-based clear cell renal cell carcinoma (ccRCC) diagnostic signature. A Scatter plots showing the expression levels of candidate emRNAs, including CUL9, KMT2D, PBRM1, PREX2, and SETD2, between localized ccRCCs (n = 106) and patients with benign renal masses (n = 73). B ROC-AUC evaluation showed the diagnostic performance of the diagnostic signature comprising CUL9, KMT2D, and PREX2 to differentiate localized ccRCCs (n = 106) from patients with benign renal masses (n = 73). C, D ROC-AUC evaluation showed the diagnostic performance of the signature comprising CUL9, KMT2D, and PREX2 to differentiate localized ccRCCs (n = 106) from patients with benign solid masses (n = 47) and benign cystic masses (n = 26). ccRCC, clear cell renal cell carcinoma; ROC, receiver operator characteristic; AUC, area under the curve